| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cybin (AMEX:CYBN) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.09) by 27.5...
https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-sugge...
https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedel...
- Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company's deuterated dimethyltryptam...
-SEC Filing
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/